Srinivas Akkaraju - ZS Pharma Insider

ZS Pharma Inc -- USA Stock  

 89.98  0.02  0.0222%

Independent Director

Dr. Srinivas Akkaraju M.D. Ph.D. is an Independent Director of ZS Pharma Inc. Dr. Akkaraju has over 16 years of investment and operational experience in the life sciences sector. Dr. Akkaraju has served as a General Partner concentrating on biopharmaceutical investments of Sofinnova Ventures since April 2013. Prior to Sofinnova Ventures Dr. Akkaraju served as a Managing Director at New Leaf Venture Partners from January 2009 to April 2013. Prior to New Leaf Venture Partners Dr. Akkaraju was a founding Managing Director at Panorama Capital the venture spinout from the arm of J.P. Morgan Partners that specialized in biotech and information technology investments. Before forming Panorama Capital he was a part of the biotech investment team of J.P. Morgan Partners from April 2001 to July 2006 most recently serving as Partner. Prior to J.P. Morgan Partners Dr. Akkaraju held business and corporate development positions at Genentech Inc. from October 1998 to March 2001. Dr. Akkarajus past board memberships have included Piramed Ltd. Eyetech Pharmaceuticals Inc. and Synageva BioPharma Corporationration He currently serves on the boards of Seattle Genetics Inc. Intercept Pharmaceuticals Inc. and Versartis Inc
Age: 46  Director Since 2014  Ph.D    
650-458-4100  http://www.zspharma.com
Akkaraju received his B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine.

Srinivas Akkaraju Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (0.99) % which means that it has lost $0.99 on every $100 spent on asset. This is way below average.
The company currently holds 10.39 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. ZS Pharma Inc has Current Ratio of 10.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

ZS Pharma, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of nonabsorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. ZS Pharma Inc (ZSPH) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 184 people. ZS Pharma is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Crypto Portfolio Optimizer Now
   

Crypto Portfolio Optimizer

Optimize portfolio of digital coins and token across multiple currency and exchanges
Hide  View All  NextLaunch Crypto Portfolio Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ZS Pharma Inc to your portfolio

Top Management

ZS Pharma Inc Leadership Team
Jeffrey Farrow, CFO
D Keyser, Director
Srinivas Akkaraju, Director, Ph.D
John Whiting, Director, MBA
Adam Tomasi, Executive, MBA
Robert Alexander, CEO, Ph.D
Marc Ostro, Director, Ph.D
Martin Babler, Director
Guy Nohra, Director, MBA
Alvaro Guillem, Founder, Ph.D
Jeffrey Keyser, COO
Cynthia Smith, Executive, MBA
Mark Asbury, President
Henrik Rasmussen, Executive, Ph.D
Kimberly Popovits, Director

Stock Performance

ZS Pharma Performance Indicators